Leerink Partners Maintains Outperform on Cogent Biosciences, Raises Price Target to $50
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Leerink Partners analyst Andrew Berens maintains Cogent Biosciences (NASDAQ:COGT) with a Outperform and raises the price target from $18 to $50.
Leerink Partners analyst Andrew Berens maintains Cogent Biosciences (NASDAQ:COGT) with a Outperform and raises the price target from $18 to $50.